MK-5172
| CAS No. | 1350514-68-9 | Cat. No. | BCP28567 |
| Name | MK-5172 | ||
| Synonyms | MK 5172; MK5172; Grazoprevir; | ||
| Formula | C38H50N6O9S | M. Wt | 766.91 |
| Description | MK-5172, also known as Grazoprevir, is a drug approved for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, following promising results in Phase II when used in combination with the NS5A replication complex inhibitor elbasvir, either with or without ribavirin.Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets. It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications. | ||
| Pathways | Protease/Metabolic Enzyme Microbiology/Virology | ||
| Targets | HCV Protease HCV | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.